CAS: 32372-82-0; Isoindoline Hydrochloride

上下游产品

CAS号6921-28-4 二炔丙胺 | CAS号74-86-2 乙炔 | CAS号38379-25-8 (2-(chloromethy... | CAS号4152-92-5 2-(氨甲基)苯甲醇 | CAS号32372-83-1 2-(甲苯-4-磺酰基)-2,... | CAS号1470-99-1 顺式全氢异吲哚

邻苯二甲酸亚胺置于bis(Cyclopentadienyl)Dihydrozirconium,频那醇硼烷,盐酸体系中,用 乙醚 用作溶剂,20.0 °C,101.33 Kpa 条件下,反应 12.0H,以79%的收率获得异吲哚啉盐酸盐
参考文献:一种酰胺化合物还原制备胺类化合物的方法
标题:一种酰胺化合物还原制备胺类化合物的方法
摘要:本发明涉及一种酰胺化合物还原制备胺类化合物的方法,该方法是指在保护气氛中,将酰胺类化合物或环状酰胺,锆金属催化剂,频哪醇硼烷混合,于室温条件下进行酰胺还原反应,12~48H后通过氯化氢的乙醚溶液后处理,即得胺的盐酸盐化合物.本发明操作简单,成本低且具有非常好的官能团耐受性和广泛的底物范围.

专利信息

专利号:WO-2009152051-A1
优先权日:2008-06-12
标题:Synthesis of a macrocyclic hcv protease inhibitor
发明人：WANG PENG
权利人:PHENOMIX CORP; WANG PENG
摘要:The present invention provides a method of synthesis of a macrocyclic compound known as a potent inhibitor of a protease produced by the hepatitis C virus (HCV). Inhibition of the viral protease blocks assembly of mature viral particles in an infected mammalian host. The method of synthesis involves a ring-closing metathesis step using a ruthenium catalyst. Hydrogenation and boronate deprotection provide the HCV protease-inhibitory product.

专利号:EP-0129461-B1
优先权日:1983-06-06
标 题:Derivatives of isoindoledicarboxylic acids, their preparation and pharmaceutical compositions thereof
摘要:1. Claims for the contracting states : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE Compounds corresponding to the general formula I : see diagramm : EP0129461,P7,F5 in which the ring A is saturated or, alternatively, benzenic, R represents a hydrogen atom or a lower alkyl group having from 1 to 4 carbon atoms, R' represents a linear alkyl radical having from 1 to 6 carbon atoms or a mono- or di-cycloalkyl-alkyl radical having from 4 to 7 carbon atoms, in their racemic form or in the form of optical isomers, and the salts thereof obtained with a therapeutically compatible mineral or organic base or the addition salts thereof obtained with a pharmaceutically compatible mineral or organic acid. 1. Claim for the contracting state : AT Process for the preparation of compounds corresponding to the general formula I : see diagramm : EP0129461,P7,F6 in which the ring A is saturated or, alternatively, benzenic, R represents a hydrogen atom or a lower alkyl group having from 1 to 4 carbon atoms, R' represents a linear alkyl radical having from 1 to 6 carbon atoms or a mono- or di-cycloalkyl-alkyl radical having from 4 to 7 carbon atoms, in their racemic form or in the form of optical isomers, and the salts thereof obtained with a therapeutically compatible mineral or organic base or the addition salts thereof obtained with a pharmaceutically compatible mineral or organic acid, characterised in that a carboxyisoindole derivative of the formula : see diagramm : EP0129461,P8,F1 in which A has the same meaning as in formula I and R' represents an alkyl group having from 1 to 6 carbon atoms, preferably a tert.-butyl group, or one of the addition salts thereof, is condensed with a functional derivative of a substituted amino acid of the formula III : see diagramm : EP0129461,P8,F2 in which R et R' have the same meanings as in formula I and the nitrogen atom is protected by a radical customarily used for protection in the synthesis of peptides, such as benzyloxycarbonyl or tert.-butoxycarbonyl, and the intermediate compound obtained is subjected to customary deprotecting processes, such as, for example, total or partial saponification, and/or hydrogenolysis, and in this manner is converted into a compound of the formula I.

专利号:US-11312722-B2
优先权日:2019-05-08
标 题:Hsp90 inhibitors and uses thereof
发明人：BROWN LAUREN ELAINE; HUANG DAVID S; COWEN LEAH E; WHITESELL LUKE; MARCYK PAUL
权利人:UNIV BOSTON; GOVERNING COUNCIL UNIV TORONTO
摘要:Herein is described the design and synthesis of resorcylate aminopyrazole compounds. These compounds show broad, potent and fungal-selective Hsp90 inhibitory activity. These compounds also find use in treating Hsp90 related diseases.